RIGEL PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
RIGL$43.91+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Income (Loss)
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net income (loss) | $367,024 | $17,485 | $(25,091) |
| Other comprehensive income: | |||
| Net unrealized gain on short-term investments | 171 | 2 | 161 |
| Comprehensive income (loss) | $367,195 | $17,487 | $(24,930) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.